Preclinical leads for innovative uses for etoposide

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Amplification of oncogenes in human tumors correlates with poor prognosis.
• Amplified oncogenes can reside in chromosomal homogeneously staining regions or extrachromosomal double minutes (DMs).
• Extrachromosomal amplified oncogenes in DMs are susceptible to cellular loss.

Purpose of the Study:

• To investigate the effect of the topoisomerase II inhibitor etoposide on DM-containing amplified oncogenes.
• To determine if etoposide can reduce the number of amplified oncogenes located in DMs.
• To explore the potential therapeutic implications of eliminating amplified oncogenes.

Main Methods:

• Treatment of three human tumor cell lines with clinically achievable concentrations of etoposide.
• Quantification of the number of double minutes (DMs) containing amplified oncogenes before and after treatment.
• Assessment of changes in amplified oncogene copy number and cellular localization.

Main Results:

• Etoposide treatment led to a significant decrease in the number of DMs in all tested tumor cell lines.
• The reduction in DMs suggests a loss of extrachromosomal amplified oncogenes.
• The observed effect was achieved with clinically relevant concentrations of etoposide.

Conclusions:

• Etoposide effectively reduces extrachromosomal amplified oncogenes located in double minutes (DMs).
• Elimination of amplified oncogenes may lead to less aggressive tumor behavior.
• Targeting DMs with etoposide represents a potential therapeutic strategy in oncology.